IGF-1 DES Reference

Plain English

What it is

IGF-1 DES is a lab-made, shortened copy of insulin-like growth factor-1 (IGF-1), a natural body protein that tells cells to grow. It is missing the first three building blocks at one end of the molecule. It is not an approved medicine and is handled as a research chemical, not something tested or cleared for use in people.

What people use it for

In bodybuilding circles, people inject it into one muscle before a workout, hoping to make that muscle grow in that spot. The marketing claim is that it sticks to far fewer carrier proteins than regular IGF-1, which is said to keep its effect more local. No human studies support these uses.

What the science shows

IGF-1 DES was created mainly as a tool for growing cells in the lab. In lab dishes it latches onto the IGF-1 receptor about as well as normal IGF-1, but it barely binds the proteins that normally carry IGF-1 around the body. There is no published human clinical program, so how it behaves and how safe it is in people are simply unknown.

The catch

It is not FDA-approved and is not a treatment. The World Anti-Doping Agency bans it in sport at all times as a growth factor, so athletes who use it can face sanctions. Documented concerns include dangerously low blood sugar and unwanted tissue overgrowth, and nothing in humans backs the way people use it.

Reference summary

IGF-1 DES was developed primarily as a cell-culture research reagent. There is no published human clinical program for DES-IGF-1. Community framing extrapolates from recombinant IGF-1 pharmacology, with an emphasis on lower IGFBP affinity producing more localized tissue effects.

Regulatory and posture

Categories

Growth Factor

Aliases

des(1-3)IGF-1, DES IGF-1, Truncated IGF-1

Evidence posture

preclinical - WADA-prohibited. No published human clinical program for IGF-1 DES. Hypoglycemia, tissue overgrowth, and anti-doping sanction are the principal documented risks, similar to IGF-1 LR3.

Regulatory status

No FDA-approved IGF-1 DES drug label. IGF-1 DES is a truncated IGF-1 analog lacking the first three N-terminal amino acids, studied in cell-culture research and sold in gray-market research-vial form. WADA prohibits IGF-1 and its analogs under category S2 at all times.

Content review status

research reference

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• Injection-site rotation overview - Public overview of the Pro site-rotation planner.